Intravenous Psilocybin Administration for Plasma-Concentration Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for using psilocybin and other psychedelics in treating psychological disorders face challenges such as potential intoxication, difficulties in controlling doses, and variability in pharmacokinetic parameters, leading to unpredictable therapeutic windows and adverse effects.
Innovation Solution
Methods involving intravenous administration of psilocybin or psilocin to induce a dissociative state, followed by maintaining a predetermined mean plasma concentration during a therapeutic window, using non-invasive brain activity measurements like EEG to control the duration and intensity of the state, allowing for precise dose determination and adverse event management.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If psilocybin is administered to treat psychological disorders, then therapeutic effects are achieved, but the risk of intoxication and adverse effects increases
Solution Approach 1:
The patent changes the physical state parameter of psilocybin from solid to liquid by dissolving it in water to create a clear solution. This parameter change enables precise dosing control and rapid absorption, achieving therapeutic effects while reducing the risk of intoxication and adverse effects through better dose management.
Solution Approach 2:
The patent replaces the traditional oral solid dosage form with an intravenous liquid administration system. This substitution allows for precise control of drug delivery, rapid onset of therapeutic effects, and better management of plasma concentration to minimize adverse effects while maintaining therapeutic efficacy.
2Reliability
If psilocybin dosage is increased to ensure therapeutic effect, then treatment effectiveness improves, but control over dose and pharmacokinetic parameters becomes difficult
Solution Approach 1:
The patent changes psilocybin from a solid compound to a liquid solution, enabling precise volumetric dosing. This parameter change allows for accurate control of dose and pharmacokinetic parameters through controlled intravenous infusion, ensuring treatment effectiveness while maintaining precise dose control.
Solution Approach 2:
The patent implements monitoring of plasma concentration and clinical response as feedback mechanisms. This allows real-time adjustment of the infusion rate to maintain optimal therapeutic levels, ensuring treatment effectiveness while preventing overdose and maintaining precise dose control throughout the administration process.
3Ease of operation
If psilocybin is administered orally as solid, then ease of administration is maintained, but absorption and pharmacokinetic variability increase
Solution Approach 1:
The patent replaces oral solid administration with intravenous liquid infusion. This substitution eliminates gastrointestinal absorption variability and first-pass metabolism, resulting in consistent and predictable pharmacokinetics while maintaining ease of administration through a standardized infusion protocol.
Solution Approach 2:
The patent changes the administration route from oral to intravenous and the physical state from solid to liquid. These parameter changes ensure complete and immediate bioavailability, eliminating pharmacokinetic variability associated with oral absorption while maintaining operational simplicity through a controlled infusion process.
Data Source
AI summary
Provided are improved methods for treating a psychological disorder in a subject comprising administering to the subject an amount of psilocybin or psilocin sufficient to induce a dissociative state in the subject less than 30 minutes after the administration; and thereafter maintaining the mean plasma concentration of the psychedelic at a predetermined value to maintain the dissociative state during a therapeutic window.